Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer

被引:0
|
作者
Tsurusaki, T
Koji, T
Sakai, H
Kanetake, H
Saito, Y
机构
[1] Nagasaki Univ, Sch Med, Dept Urol, Nagasaki 8528501, Japan
[2] Nagasaki Univ, Sch Med, Dept Histol & Cell Biol, Nagasaki 8528501, Japan
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study was undertaken to define the relationship between histological grade (Gleason grade) and prostate-specific antigen (PSA) mRNA expression and to evaluate the level of PSA mRNA expression as a possible prognostic marker for untreated prostate cancers. The primary grade areas of 104 prostatic biopsy specimens were analyzed for the expression of PSA mRNA and its protein by nonradioactive in situ hybridization and immunohistochemistry, respectively. A multivariate survival analysis was performed to examine the correlation between PSA mRNA expression and several clinicopathological parameters, e.g., the immunostaining level of PSA protein in biopsy specimens. The percentage of specimens positive for PSA mRNA increased significantly with advanced histological grade. Image analysis of the signal intensity for PSA mRNA showed a significant correlation between the signal intensity in both primary and secondary grade areas of each specimen and the histological grade (P < 0.0001), Only 26.0% of specimens positive for PSA protein were also positive for PSA mRNA (and sice versa, 6.7%). Other tumors were either positive for both (66.3%) or negative for both (1.0%), When the Cox's proportional hazards regression model was used to analyze cancer-specific survival, untreated patients with higher levels of PSA mRNA expression in the higher grade (representing higher grade of either primary or secondary grade) area of tumors were at high risk for cancer-related death (P = 0.017), Furthermore, in cancer-specific survival curves based on PSA mRNA expression status, patients with high levels of PSA mRNA expression in the higher grade area of tumors had a significantly poorer prognosis (P = 0.001), compared with those with tumors expressing low levels of PSA mRNA, Our results suggested that analysis of PSA mRNA expression in specific areas in biopsy specimens of patients with untreated prostate cancer may provide a good assessment of prognosis of prostate cancers.
引用
收藏
页码:2187 / 2194
页数:8
相关论文
共 50 条
  • [21] Prostate specific antigen (PSA) as a diagnostic and prognostic marker of prostate cancer
    Simon, Ronald
    Kluth, Martina
    Fischer, Kristine
    Bonk, Sarah
    Hube-Magg, Claudia
    Hoflmayer, Doris
    Lennartz, Maximilian
    Lutz, Florian
    Sauter, Guido
    Buescheck, Franziska
    Uhlig, Ria
    Dum, David
    Luebke, Andreas M.
    Wittmer, Corinna
    Jacobsen, Frank
    Burandt, Eike
    Steurer, Stefan
    Minner, Waldemar Wilczakand Sarah
    CANCER RESEARCH, 2019, 79 (13)
  • [22] DESIGN OF A TIME-RESOLVED FLUOROMETRIC HYBRIDIZATION ASSAY FOR THE MESSENGER-RNA OF PROSTATE-SPECIFIC ANTIGEN
    GALVAN, B
    CHRISTOPOULOS, TK
    DIAMANDIS, EP
    CLINICAL CHEMISTRY, 1995, 41 (11) : 42 - 42
  • [23] Prostate cancer screening with prostate-specific antigen in hemodialysis patients
    Horinaga, Minoru
    Kitamura, Koji
    Saito, Shiro
    Ukimura, Osamu
    Nakanoma, Takashi
    Okihara, Koji
    Kitagawa, Motonobu
    Nakanishi, Hiroyuki
    Miki, Tsuneharu
    UROLOGIA INTERNATIONALIS, 2007, 78 (04) : 334 - 337
  • [24] Induction of prostate-specific antigen expression by synthetic progestins in patients with prostate and breast cancer
    Diamandis, EP
    MAYO CLINIC PROCEEDINGS, 1998, 73 (07) : 706 - 707
  • [25] Prostate-specific membrane antigen: Much more than a prostate cancer marker
    Chang, SS
    Gaudin, PB
    Reuter, VE
    O'Keefe, DS
    Bacich, DJ
    Heston, WDW
    MOLECULAR UROLOGY, 1999, 3 (03) : 313 - 319
  • [26] IS PROSTATE-SPECIFIC ANTIGEN THE MOST USEFUL MARKER FOR SCREENING IN PROSTATE-CANCER
    DELAERE, KPJ
    VANDIEIJENVISSER, MP
    GIJZEN, AHJ
    BROMBACHER, PJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 : S65 - S67
  • [27] The pretreatment prostate-specific antigen doubling time: clinical and prognostic values in patients with prostate cancer
    Zharinov, G. M.
    Bogomolov, O. A.
    ONKOUROLOGIYA, 2014, 10 (01): : 44 - 48
  • [28] Prostate-specific membrane antigen expression predicts prostate cancer recurrence
    不详
    ONCOLOGY-NEW YORK, 2006, 20 (07): : 790 - 790
  • [29] PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION AND PROSTATE CANCER SURVIVAL
    Kasperzyk, Julie
    Finn, Stephen
    Hendrickson, Whitney
    Flavin, Richard
    Fiorentino, Michelangelo
    Giovannucci, Edward
    Stampfer, Meir
    Loda, Massimo
    Mucci, Lorelei
    ANTICANCER RESEARCH, 2010, 30 (04) : 1535 - 1536
  • [30] Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
    Perner, Sven
    Hofer, Matthias D.
    Kim, Robert
    Shah, Rajal B.
    Li, Haojie
    Moeller, Peter
    Hautmann, Richard E.
    Gschwend, Juergen E.
    Kuefer, Rainer
    Rubin, Mark A.
    HUMAN PATHOLOGY, 2007, 38 (05) : 696 - 701